Focus on atorvastatin: An HMG-CoA reductase inbibitor for lowering both elevated LDL cholesterol and triglycerides in hypercholesterolemic patients

Formulary

Volumn 32, Issue 4, 1997, Pages 352-363

  Kellick, Kenneth A ^a   Burns, Kathleen ^a   Mcandrew, Elizabeth ^a   Haberl, Evelyn ^a   Hook, Nancy ^a   Ellis, Avery K ^b  

^a VA W New York Healthcare System   (United States)

^b VAWNYHS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; REVIEW; TREATMENT OUTCOME;

EID: 0030972431     PISSN: 00986909     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Atorvastatin (Lipitor) prescribing information. Morris Plains, NJ: Warner-Lambert Company, December 1996.
2. Bocan TM, Ferguson E, McNally W, et al. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitors. Biochemica et Biophysica Acta 1992;1123:133-44.
3. Levy RI, Troendle AJ, Fattu JM. A quarter century of drug treatment of dyslipoproteinemia with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 1993;87(Suppl III); III45-III53.
4. Physician's Desk Reference, Medical Economics Co, Montvale NJ, 1997.
5. Gibson DM, Bron NJ, Richens A, et al. Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol 1996;36:242-6.
6. Posvar EL, Radulovic LL, Cilla DD, et al. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J Clin Pharmacol 1996;36:728-31.
7. Cilla DD, Whitfield LR, Gibson DM, et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 1996;60:687-95.
8. Cilla DD, Gibson DM, Whitfield LR, Sedman AJ. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol 1996;36:604-9.
9. Radulovic LL, Cilla DD, Posvar EL, et al. Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol 1995;35:990-4.
10. Data on file, Parke-Davis, a Division of Warner-Lambert.
11. Heinonen TM, Stein E, Weiss SR, et al. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: Results of a randomized, double-masked study. Clin Ther 1996;18: 853-63.
12. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vase Biol 1995; 15:678-82.
13. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor atorvastatin, in patients with hypertriglyceridemia. JAMA 1996;275:128-33.
14. Best JD, Nicholson GC, O'Neal DN, et al. Atorvastatin and simvastatin reduce elevated cholesterol in non-insulin dependent diabetics. Diab Nutr Metab 1996;9:74-80.
15. Bracs P, Best J, Dart T, et al. A one-year study comparing atorvastatin and simvastatin in patients with hypercholesterolemia (abstract). European Atherosclerosis Society 66th Congress Proceedings, Florence, Italy 1996, pg 205.
16. Bertolini S, Bittolo Bon G, Campbell M, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis, in press.
17. Bakker-Arkema R, Fayyad R, Davidson M, et al. One-year study comparing the safety and efficacy of atorvastatin to that of lovastatin (abstract). European Atherosclerosis Society 66th Congress Proceedings, Florence, Italy 1996, pg 205.
18. Heinonen T, Schrott H, Broyles L, et al. The effects of atorvastatin in postmenopausal women. European Atherosclerosis Society 66th Congress Proceedings, Florence, Italy 1996, pg 56.
19. McCormick L, Black D. A 12-week study comparing atorvastatin with niacin in patients with hypertriglyceridemia with or without hypercholesterolemia. European Atherosclerosis Society 66th Congress Proceedings, Florence, Italy 1996, pg 204.
20. Bakker-Arkema RG, Best J, Fayyad R, et al. Efficacy and safety of atorvastatin as evidenced by a pooled analysis of early clinical trials. Atherosclerosis, in press.
21. Heinonen TM, Schrott H, McKenney JM, et al. Atorvastatin, a new HMG-CoA reduclase inhibitor as monotherapy and combined with colestipol. J Cardiovasc Pharmacol Ther 1996;1:117-22.
22. Smith Jr SC, Blair SN, Criqui MH, et al. AHA consensus panel statement. Preventing heart attack and death in patients with coronary disease. The Secondary Prevention Panel. J Am Coll Cardiol 1995;26:292-4.